Lax S F
Institut für Klinische Pathologie und Molekularpathologie, LKH Graz II, Standort West, Akademisches Lehrkrankenhaus der Medizinischen Universität Graz, Göstinger Straße 22, 8020, Graz, Österreich.
Pathologe. 2019 Feb;40(1):46-60. doi: 10.1007/s00292-019-0572-9.
Epithelial ovarian tumors may cause various diagnostic problems of practical relevance. For the distinction between cystadenomas and borderline tumors/atypically proliferative tumors, a minimum extent of 10% of the atypical epithelial proliferation has been suggested by the WHO. The micropapillary variant of serous borderline tumors is more frequently associated with invasive growth and extraovarian lesions. Extraovarian lesions of borderline tumors are relevant for prognosis and cause a higher stage; their classification is crucial. Traditionally, they were classified into noninvasive and invasive implants based on their morphology. Based on the 2014 WHO classification, invasive lesions should be designated as low-grade serous carcinomas whereas only noninvasive lesions are considered implants. The most frequent invasive growth pattern in low-grade serous carcinomas consists of haphazardly arranged tumor cell nests and small papillae in clefts, whereas mucinous and endometrioid carcinomas mainly show a confluent glandular pattern with maze-like and cribriform structures. For metastatic mucinous tumors a nodular growth pattern is characteristic; ruling them out requires clinical information including imaging and immunohistochemistry. Differential diagnosis between low-grade and high-grade serous carcinoma is based on the degree of nuclear polymorphism and mitotic count. The seromucinous tumor category replaces the endocervical subtype of mucinous tumors and resembles histologically, biologically, and on the molecular level serous and endometrioid tumors. Endometrioid tumors with fibromatous stroma need to be distinguished from tumors with Sertoli cell differentiation and well-differentiated neuroendocrine tumors. For differential diagnosis of epithelial ovarian tumors, in particular carcinomas, a panel of antibodies for immunohistochemistry is very useful under consideration of histomorphology.
上皮性卵巢肿瘤可能会引发各种具有实际意义的诊断问题。对于区分囊腺瘤与交界性肿瘤/非典型增生性肿瘤,世界卫生组织(WHO)建议非典型上皮增生的最小范围为10%。浆液性交界性肿瘤的微乳头变体更常与浸润性生长和卵巢外病变相关。交界性肿瘤的卵巢外病变与预后相关且会导致分期升高;其分类至关重要。传统上,它们根据形态学被分为非浸润性和浸润性种植体。根据2014年WHO分类,浸润性病变应被指定为低级别浆液性癌,而只有非浸润性病变才被视为种植体。低级别浆液性癌最常见的浸润性生长模式由裂隙中杂乱排列的肿瘤细胞巢和小乳头组成,而黏液性癌和子宫内膜样癌主要表现为具有迷宫样和筛状结构的融合腺管模式。对于转移性黏液性肿瘤,结节状生长模式是其特征;排除它们需要包括影像学和免疫组织化学在内的临床信息。低级别和高级别浆液性癌的鉴别诊断基于核多形性程度和有丝分裂计数。浆液黏液性肿瘤类别取代了黏液性肿瘤的宫颈内膜亚型,在组织学、生物学和分子水平上类似于浆液性和子宫内膜样肿瘤。具有纤维瘤性间质的子宫内膜样肿瘤需要与具有支持细胞分化的肿瘤和高分化神经内分泌肿瘤相鉴别。对于上皮性卵巢肿瘤,尤其是癌的鉴别诊断,在考虑组织形态学的情况下,一组免疫组织化学抗体非常有用。